🔎 Trials Near Me

Home › Pituitary Tumors › NCT07456878

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

RecruitingPhase 1

Who can join

Ages 18 to 75 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
* Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
* Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
* Able to provide informed consent and be capable of completing the imaging protocols.
* Female subjects of childbearing potential (women of childbearing potential \[WOCBP\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.

Exclusion Criteria:

* Patients with contraindications to MRI or PET scans.
* Patients with known allergies to contrast agents or other imaging-related materials.
* Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
* Patients with successful MRI localization of the adenoma.

About the study

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

What is being tested

Sponsor: Mayo Clinic · Participants: 5 · Started: Jan 8, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07456878

Locations in the U.S.

FloridaMayo Clinic, Jacksonville

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.